Watson Ashley 4

4 · Merck & Co., Inc. · Filed Nov 1, 2018

Form 4

Period: 2018-10-31

SVP Chief Ethics & Com Officer

Transactions

Exercise/Conversion
Stock Option (right to buy)
2018-10-31−5,706→ 11,412 total
Exercise: $63.97From: 2018-05-05Exp: 2027-05-04→ Common Stock (5,706 underlying)
Exercise/Conversion
Stock Option (right to buy)
2018-10-31−18,110→ 9,055 total
Exercise: $54.68From: 2017-05-10Exp: 2026-05-09→ Common Stock (18,110 underlying)
Exercise/Conversion
Common Stock
2018-10-31$59.86/sh+23,220$1,389,949→ 32,990.119 total
Exercise/Conversion
Common Stock
2018-10-31$63.97/sh+5,706$365,013→ 56,806.119 total
Exercise/Conversion
Stock Option (right to buy)
2018-10-31−23,220→ 0 total
Exercise: $59.86From: 2016-05-01Exp: 2025-04-30→ Common Stock (23,220 underlying)
Exercise/Conversion
Common Stock
2018-10-31$54.68/sh+18,110$990,255→ 51,100.119 total
Sale
Common Stock
2018-10-31$74.33/sh−47,036$3,496,158→ 9,770.119 total

Holdings

Footnotes (6)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.1200 to $74.4500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
[F2]Holdings include shares acquired in dividend reinvestment transactions.
[F3]Includes shares acquired and dividends earned through October 5, 2018, in the Merck U.S. Savings Plan, a 401(k) plan.
[F4]The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018.
[F5]The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020.
[F6]The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.

Documents

1 file